Guardant Health struck a strategic collaboration with Zephyr AI to combine Guardant’s multimodal molecular datasets from its genomic testing platform with Zephyr’s AI and machine learning analytics to discover and validate novel cancer biomarkers. The partnership will integrate with Guardant’s Infinity AI capabilities to support predictive biomarker generation for drug development and therapeutic selection. Guardant said the alliance aims to speed biomarker identification, improve targeted therapy predictions and enhance trial design for biopharma partners. The companies plan to deploy joint analytics across Guardant’s clinical sequencing data and Zephyr’s modeling tools to advance precision oncology research.